Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ)

Virtu Financial LLC purchased a new position in shares of Mainz Biomed (NASDAQ:MYNZ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 18,330 shares of the company’s stock, valued at approximately $79,000.

Wall Street Analysts Forecast Growth

Separately, Maxim Group initiated coverage on Mainz Biomed in a research report on Friday, February 14th. They set a “buy” rating and a $14.00 price objective for the company.

Mainz Biomed Stock Performance

MYNZ stock opened at $3.21 on Tuesday. The stock has a market capitalization of $6.42 million, a PE ratio of -0.05 and a beta of 0.33. The company has a fifty day moving average of $5.37 and a 200-day moving average of $7.25. Mainz Biomed has a one year low of $2.88 and a one year high of $45.20.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.